Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-label Study of GE-148 (18F) PET Imaging in Prostate Cancer Prior to Radical Prostatectomy
2010-018311-15Phase 2Terminated
- Sponsor
- GE HealthCare
- Start
- Apr 2010
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluciclovine f 18 in prostate cancer (PCa), sponsored by GE HealthCare. Primary endpoints: Primary: Uptake and retention of GE-148 (18F) in prostate tissues and Primary: Relationship between tracer uptake and Gleason score. Started Apr 2010; status: terminated.
02
Drugs
fluciclovine f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2010-018311-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018311-15.